Evidence map›Paper›PMID 39457986›Full record

ReviewJournal of clinical medicine2024

From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.

Bridget E Crossman, Regan L Harmon, Kourtney L Kostecki, Nellie K McDaniel, Mari Iida, Luke W Corday, Christine E Glitchev, Madisen T Crow, Madelyn A Harris, Candie Y Lin and 18 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Cancer Immunotherapy-An Overview.Cancer treatment and research · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Bridget E CrossmanDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.ORCID 0009-0006-8274-9104
Regan L HarmonDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Kourtney L KosteckiDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.ORCID 0000-0003-2289-5194
Nellie K McDanielDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Mari IidaDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.ORCID 0000-0001-7168-8680
Luke W CordayDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Christine E GlitchevDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.ORCID 0009-0008-2833-878X
Madisen T CrowDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Madelyn A HarrisDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Candie Y LinDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Jillian M AdamsDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Colin A LonghurstDepartments of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI 53726, USA.ORCID 0000-0002-2548-9610
Kwangok P NickelDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.ORCID 0000-0003-0263-128X
Irene M OngDepartments of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI 53726, USA.
Roxana A AlexandridisDepartments of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI 53726, USA.
Menggang YuDepartment of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA.
David T YangDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53705, USA.ORCID 0000-0002-9488-1704
Rong HuCarbone Cancer Center, University of Wisconsin, Madison, WI 53792, USA.
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Gregory K HartigDepartment of Surgery, University of Wisconsin, Madison, WI 53705, USA.
Tiffany A GlazerDepartment of Surgery, University of Wisconsin, Madison, WI 53705, USA.
Sravani RamisettyDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Prakash KulkarniDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Ravi SalgiaDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0001-9643-7626
Randall J KimpleDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.ORCID 0000-0001-8336-8000
Justine Y BruceCarbone Cancer Center, University of Wisconsin, Madison, WI 53792, USA.ORCID 0000-0002-5902-7430
Paul M HarariDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Deric L WheelerDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.

Funding

Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Zachary Scott Morris · 2022 to 2026
$12.5M
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNCR01CA262292 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Ravi Salgia, DERIC L WHEELER · 2022 to 2026
$2.9M
NIH HHS 1P50CA278595-07A1NIH HHS 1R01CA262292-03A1
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is diagnosed in more than 71,000 patients each year in the United States, with nearly 16,000 associated deaths. One significant hurdle in the treatment of HNSCC is acquired and intrinsic resistance to existing therapeutic agents. Over the past several decades, the University of Wisconsin has formed a multidisciplinary team to move basic scientific discovery along the translational spectrum to impact the lives of HNSCC patients. In this review, we outline key discoveries made throughout the years at the University of Wisconsin to deepen our understanding of therapeutic resistance in HNSCC and how a strong, interdisciplinary team can make significant advances toward improving the lives of these patients by combatting resistance to established therapeutic modalities. We are profoundly grateful to the many scientific teams worldwide whose groundbreaking discoveries, alongside evolving clinical paradigms in head and neck oncology, have been instrumental in making our work possible.

Indexed as

AxlcetuximabEGFRHNSCCMerTKresistanceTAMs

Identifiers

PMID39457986
PMCPMC11508784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.